Improvement of cancellous bone microstructure in patients on. teriparatide following alendronate pretreatment

被引:19
|
作者
Fahrleitner-Pammer, Astrid [1 ]
Burr, David [2 ]
Dobnig, Harald [1 ]
Stepan, Jan J. [3 ,4 ]
Petto, Helmut [5 ]
Li, Jiliang [6 ]
Krege, John H. [7 ]
Pavo, Imre [5 ]
机构
[1] Med Univ Graz, Dept Internal Med, Div Endocrinol & Metab, Auenbruggerpl 15, A-8036 Graz, Austria
[2] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN USA
[3] Charles Univ Prague, Inst Rheumatol, Prague, Czech Republic
[4] Charles Univ Prague, Fac Med 1, Prague, Czech Republic
[5] Lilly Res Ctr, Vienna, Austria
[6] Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN USA
[7] Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN USA
关键词
Teriparatide; PINP; Cancellous bone microstructure; Alendronate pretreatment; Tumover markers; PARATHYROID-HORMONE; 1-34; POSTMENOPAUSAL WOMEN; BIOCHEMICAL MARKERS; MINERAL DENSITY; SEVERE OSTEOPOROSIS; BMD RESPONSE; THERAPY; TURNOVER; STRENGTH; PINP;
D O I
10.1016/j.bone.2016.05.004
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An increase in procollagen type I amino-terminal propeptide (PINP) early after teriparatide initiation was shown to correlate with increased lumbar spine areal BMD and is a good predictor of the anabolic response to teriparatide. Few data exist correlating PINP and bone microstructure, and no data exist in patients on teriparatide following prior potent antiresorptive treatment. This exploratory analysis aimed to investigate the effects of teriparatide on cancellous bone microstructure and correlations of bone markers with microstructure in alendronate-pretreated patients. This was a post hoc analysis of changes in bone markers and three-dimensional indices of bone microstructure in paired iliac crest biopsies from a prospective teriparatide treatment study in postmenopausal women with osteoporosis who were either treatment-naive (TN, n = 16) or alendronate-pretreated (ALN, n = 29) at teriparatide initiation. Teriparatide (20 mu g/day) was given for 24 months; biopsies were taken at baseline and endpoint, and serum concentrations of PINP and type 1 collagen cross-linked C-telopeptide (beta CTX) were measured at intervals up to 24 months. In the TN and ALN groups, respectively, mean (SD) increases in three-dimensional bone volume/tissue volume were 105 (356)% (P = 0.039) and 55 (139)% (P < 0.005) and trabecular thickness 30.4 (30)% (P < 0.001) and 30.8 (53)% (P < 0.001). No significant changes were observed in trabecular number or separation. In the ALN patients, 3-month change of neither PINP nor beta CTX correlated with indices of cancellous bone microstructure. However, 12-month changes in biochemical bone markers correlated significantly with improvements in bone volume/tissue volume, r = 0.502 (P < 0.01) and r = 0.378 (P < 0.05), trabecular number, r = 0.559 (P < 0.01) and r = 0.515 (P < 0.01), and reduction of trabecular separation, r = -0.432 (P < 0.05) and r = -0.530 (P < 0.01), for PINP and SCDC, respectively. We conclude that cancellous bone microstructure improved with teriparatide therapy irrespective of prior antiresorptive use. (C) 2016 The Authors. Published by Elsevier Inc.
引用
收藏
页码:16 / 24
页数:9
相关论文
共 39 条
  • [1] TRABECULAR BONE SCORE IN PATIENTS WITH CHRONIC GLUCOCORTICOID OSTEOPOROSIS TREATED WITH ALENDRONATE OR TERIPARATIDE
    Saag, K. G.
    Agnusdei, D.
    Hans, D.
    Kohlmeier, L. A.
    Krohn, K. D.
    Leib, E. S.
    Maclaughlin, E. J.
    See, K.
    Simonelli, C.
    Taylor, K. A.
    Marcus, R.
    OSTEOPOROSIS INTERNATIONAL, 2015, 26 : S84 - S85
  • [2] Bone formation markers in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate
    Eastell, Richard
    Chen, Peiqi
    Saag, Kenneth G.
    Burshell, Alan L.
    Wong, Mayme
    Warner, Margaret R.
    Krege, John H.
    BONE, 2010, 46 (04) : 929 - 934
  • [3] Responsiveness of bone turnover markers to teriparatide is greater and earlier following treatment with risedronate compared with alendronate: The optamise study
    Boonen, S.
    Delmas, P. D.
    Watts, N. B.
    Lindsay, R.
    Miller, P.
    Stewart, J.
    Bilezikian, J. P.
    CALCIFIED TISSUE INTERNATIONAL, 2008, 82 : S214 - S215
  • [4] Change in spinal bone mineral density as estimated by Hounsfield units following osteoporosis treatment with romosozumab, teriparatide, denosumab, and alendronate: an analysis of 318 patients
    Mikula, Anthony L.
    Lakomkin, Nikita
    Hamouda, Abdelrahman M.
    Everson, Megan C.
    Pennington, Zach
    Kumar, Rahul
    Pinter, Zachariah W.
    Martini, Michael L.
    Bydon, Mohamad
    Kennel, Kurt A.
    Baffour, Francis
    Nassr, Ahmad
    Freedman, Brett
    Sebastian, Arjun S.
    Abode-Iyamah, Kingsley
    Anderson, Paul A.
    Fogelson, Jeremy L.
    Elder, Benjamin D.
    JOURNAL OF NEUROSURGERY-SPINE, 2024, 41 (03) : 309 - 315
  • [5] Trabecular Bone Score in Patients With Chronic Glucocorticoid Therapy-Induced Osteoporosis Treated With Alendronate or Teriparatide
    Saag, Kenneth G.
    Agnusdei, Donato
    Hans, Didier
    Kohlmeier, Lynn A.
    Krohn, Kelly D.
    Leib, Edward S.
    MacLaughlin, Edmund J.
    Alam, Jahangir
    Simonelli, Christine
    Taylor, Kathleen A.
    Marcus, Robert
    ARTHRITIS & RHEUMATOLOGY, 2016, 68 (09) : 2122 - 2128
  • [6] Bone turnover markers demonstrate greater earlier responsiveness to teriparatide following treatment with risedronate compared with alendronate: The OPTAMISE study
    Delmas, P.
    Watts, N.
    Miller, P.
    Cahall, D. E.
    Bilezikian, J.
    Lindsay, R.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S27 - S27
  • [7] Correlations between bone turnover markers and BMD in patients treated with teriparatide or alendronate for glucocorticoid-induced osteoporosis
    Burshell, A. L.
    Moericke, R.
    Correa-Rotter, R.
    Chen, P.
    Warner, M. R.
    Krege, J. H.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S128 - S128
  • [8] Comparative efficacy and safety of alendronate and teriparatide in bone loss reduction and prevention of vertebral fracture in osteoporotic Chinese patients
    Qi, Yujun
    Wang, Wenyuan
    Sun, Wenlin
    Pan, Qiuyin
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2021, 20 (10) : 2199 - 2204
  • [9] Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate
    Burshell, Alan L.
    Moericke, Ruediger
    Correa-Rotter, Ricardo
    Chen, Peiqi
    Warner, Margaret R.
    Dalsky, Gail P.
    Taylor, Kathleen A.
    Krege, John H.
    BONE, 2010, 46 (04) : 935 - 939
  • [10] Re-establishment of normal cancellous bone turnover does not differ following the withdrawal of alendronate or risedronate treatment in ovariectomized rats
    Fuchs, RK
    Burr, DB
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S170 - S170